Inventor · disambiguated record
Trevor Stitt
Also filed as: STITT TREVOR
8 granted patents·8 pending applications·264 citations·filing 1994–2023
89Inventor score
Top patents by PatentIndex Score
16 records- 0197US8871209B2Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin AREGENERON PHARMA·Filed 2012·Granted Oct 28, 2014·125 cites·11 claims
- 0296US9260515B2Antibodies to human GDF8REGENERON PHARMA·Filed 2014·Granted Feb 16, 2016·86 cites·6 claims
- 0391US8840894B2Antibodies to human GDF8STITT TREVOR·Filed 2011·Granted Sep 23, 2014·24 cites·5 claims
- 0487US10400036B2Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin AREGENERON PHARMA·Filed 2018·Granted Sep 3, 2019·4 cites·18 claims
- 0587US7632503B2Method of treating a muscle-related condition with modified IGF1 polypeptidesREGENERON PHARMA·Filed 2008·Granted Dec 15, 2009·7 cites·2 claims
- 0685US9890212B2Antibodies to human GDF8REGENERON PHARMA·Filed 2015·Granted Feb 13, 2018·4 cites·14 claims
- 0784US2024117027A1Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin aREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0880US2024067712A1Antibodies to human gdf8REGENERON PHARMA·Filed 2022·Application pending·0 cites
- 0973US11655291B2Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin AREGENERAN PHARMACEUTICALS INC·Filed 2019·Granted May 23, 2023·0 cites·22 claims
- 1066US2024182561A1Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscleREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1164US2015010568A1Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin aREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 1260US2019023777A1Antibodies to human gdf8REGENERON PHARMA·Filed 2018·Application pending·0 cites
- 1360US2017226197A1Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin aREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 1459US2017008956A1Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin aREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 1558US5622862AAssay systems for trkB neurotrophin activityREGENERON PHARMA·Filed 1994·Granted Apr 22, 1997·14 cites·1 claims
- 1658US2025017183A1Non-human animals comprising a modified cacng1 locusREGENERON PHARMA·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Trevor Stitt files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →